Chongning Zhong

Chongning Zhong

Auto-generated profile, based on publicly available information

Chongning Zhong

Yanbian University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2024 in The FASEB Journal
Verified
Journal Article
Open access
CZChongning Zhong
Chongning Zhong
HDHui Dong
Hui Dong
YMYuting Ma
Yuting Ma
BZBingqi Zhuang
Bingqi Zhuang
HSHongyang Shi
Hongyang Shi
Lan HongLan Hong
Lan Hong
Myocardial ischemia‐reperfusion injury (MIRI) is a significant risk factor for acute myocardial infarction and is closely associated with ferroptosis. This study aimed to identify key ferroptosis‐related genes as potential diagnostic markers for MIRI and to explore their roles in immune infiltration and therapeutic targeting in myocardial tissue. We obtained single‐cell RNA sequencing (scRNA‐seq) and RNA‐seq data on MIRI from the GEO database, applied Seurat and UMAP for data processing and clustering, and analyzed ligand‐receptor interactions using CellPhoneDB. By scoring ferroptosis in cardiomyocytes, we identified differentially expressed genes and conducted GO and KEGG pathway analyses. A protein interaction network was then constructed using the STRING database, and seven key genes (Atp5h, Vdac2, Pkm, Cycs, Hspa8, Tpi1, Ldha) were identified through Lasso regression modeling, showing significant associations with immune responses. In vivo experiments in a mouse ischemia‐reperfusion model confirmed the roles of these seven genes in MIRI via RT‐qPCR. To further investigate the role of Hspa8 in ferroptosis and MIRI, siRNA knockdown experiments were performed in H9C2 rat cardiomyocytes, and its involvement in ferroptosis was validated by JC‐1 staining and PCR analysis. This study reveals the importance of ferroptosis‐related genes in MIRI through integrated bioinformatics and experimental approaches, offering new insights into diagnostic markers and immune‐related therapeutic targets for MIRI.

3 November 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
CHChaoqun Huang
Chaoqun Huang
SSShangzhi Shu
Shangzhi Shu
XYXueling Yue
Xueling Yue
JPJinshun Piao
Jinshun Piao
MNMegumi Narisawa
Megumi Narisawa
SLShuyan Li
Shuyan Li
Background: Pathological cardiac hypertrophy is a key precursor to heart failure. PAI‐1 (plasminogen activator inhibitor‐1) is a recognized profibrotic mediator, yet its role in the heart remains paradoxical and incompletely understood. Methods: Six‐week‐old male wild‐type (PAI‐1 +/+ ) and PAI‐1 knockout (PAI‐1 −/− ) mice underwent sham or transverse aortic constriction surgery, followed by assessment of cardiac morphology, molecular markers, and function. In H9C2 cardiomyocytes, PAI‐1 was silenced or overexpressed before angiotensin II stimulation, with or without targeted signaling inhibitors, followed by coimmunoprecipitation, Western blotting, and immunofluorescence. Results: Pressure overload increased plasma and myocardial PAI‐1 levels. PAI‐1 deficiency exacerbated transverse aortic constriction‐induced cardiac dysfunction, hypertrophy, and fibrosis, accompanied by JAK2/STAT3 (Janus kinase 2/signal transducer and activator of transcription 3) activation and collagen overexpression, whereas cardiac‐specific overexpression attenuated these maladaptive changes. Moreover, STAT3 inhibition reversed the adverse cardiac remodeling associated with PAI‐1 deletion. In vitro, PAI‐1 knockdown potentiated angiotensin II‐induced cardiomyocyte hypertrophy, an effect that was rescued by PAI‐1 overexpression. Mechanistically, PAI‐1 associated with JAK2 and STAT3, with reduced phosphorylation of both proteins and impaired STAT3 nuclear translocation. Critically, pharmacological inhibition of STAT3 abolished the harmful effects of PAI‐1 silencing. Conclusions: PAI‐1 acts as an endogenous cardioprotective checkpoint by negatively regulating JAK2/STAT3 signaling. These findings suggest a noncanonical cardiomyocyte‐associated function of PAI‐1 beyond its classical fibrinolytic role and identify the PAI‐1—JAK2/STAT3 axis as a potential therapeutic target for heart failure with hypertrophy.